Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment

Abstract : Background: Immune checkpoint inhibitors (ICI) target T cell inhibitory pathways that are responsible for cancer tolerance by down-modulating immune functions. ICI have revolutionized patients care with lung cancer. Nevertheless, restoring endogenous antitumor T-cell responses can induce immune related adverse events, such as sarcoidosis. Case presentation: We report here the first case of a thoracic and cutaneous sarcoid-like reaction in a patient with a relapsing unresectable non-small cell lung cancer (NSCLC) treated with nivolumab, an anti-PD-1 mAb. The expression of PD-1 and its ligands, PD-L1 and PD-L2, was assessed by flow cytometry on peripheral blood mononuclear cells (PBMC) and compared to patients who had discontinued nivolumab therapy without having developed any immune related adverse events. PD-L1 expression was transiently increased on B cells, T cells and monocytes, whereas PD-L2 expression was not modulated. PD-1 was transiently undetectable when PD-L1 was maximal, before returning to basal level. Sarcoidosis spontaneously resolved, without corticotherapy. Conclusion: This case sheds the light on a complex regulation of PD-L1 expression in vivo on PBMC after nivolumab arrest and triggers the question of monitoring the expression of immune checkpoint on immune cells during and after treatment with ICI.
Document type :
Journal articles
Complete list of metadatas

Cited literature [12 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01817689
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, June 18, 2018 - 11:43:28 AM
Last modification on : Friday, October 4, 2019 - 1:49:48 AM

File

2018_L PaolinL_J Immunother Ca...
Publisher files allowed on an open archive

Identifiers

Citation

Léa Paolini, Caroline Poli, Simon Blanchard, Thierry Urban, Anne Croué, et al.. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment. Journal for Immunotherapy of Cancer, London : BioMed Central, 2013-, 2018, 6 (1), pp.52. ⟨10.1186/s40425-018-0372-4⟩. ⟨inserm-01817689⟩

Share

Metrics

Record views

240

Files downloads

156